Tuesday, January 12, 2016

Repetitive transcranial magnetic stimulation (rTMS) is known to be a safe, noninvasive, treatment for major depressive disorder (MDD), but how does cost compare with that of pharmacotherapy?


Australian researchers compared the cost-effectiveness of rTMS with pharmacotherapy in treatment-resistant patients with MDD (ie, those who have failed at least 2 courses of antidepressant therapy).1 They found that, although both pharmacotherapy and rTMS are clinically effective, rTMS is more cost-effective.

Considering that up to 40% of patients with MDD either do not respond to or tolerate pharmacotherapy and that up to 85% of patients who do respond can be expected to relapse within 15 years, exploration of methods that more economically sustain quality of life is worthwhile.





- See more at: http://www.psychiatrictimes.com/major-depressive-disorder/tms-cost-effective/page/0/1#sthash.baXOaVL1.dpuf  


Have questions or need assistance?

Give us a call at (615) 379-8600 or contact us, we’re here for you.